Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2022; 11(03): 269-273
DOI: 10.1055/s-0041-1740326
Original Article
Pediatric Cancer

Clinicoepidemiological Profile and Treatment Outcomes in Children with Retinoblastoma: Experience from a Cancer Care Center in Northeast India

Munlima Hazarika
1   Department of Medical oncology, Dr. B Borooah Cancer Institute, Guwahati, Assam, India
,
Gaurav Kumar
1   Department of Medical oncology, Dr. B Borooah Cancer Institute, Guwahati, Assam, India
,
Bhargab Jyoti Saikia
1   Department of Medical oncology, Dr. B Borooah Cancer Institute, Guwahati, Assam, India
,
Satya Sadhan Sarangi
1   Department of Medical oncology, Dr. B Borooah Cancer Institute, Guwahati, Assam, India
,
Partha Sarathi Roy
1   Department of Medical oncology, Dr. B Borooah Cancer Institute, Guwahati, Assam, India
,
Kasturi Bhattacharjee
2   Department of Ophthalmology, Srimanta Sankaradeva Nethralaya, Guwahati, Assam, India
,
Manabjyoti Barman
2   Department of Ophthalmology, Srimanta Sankaradeva Nethralaya, Guwahati, Assam, India
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Zoom Image
Gaurav Kumar

Background Retinoblastoma (RB) is the most common primary intraocular malignancy in children. We sought to provide a comprehensive assessment of epidemiological profile and treatment outcomes of children with RB.

Methods In this retrospective study, we analyzed 189 children diagnosed with RB at our center between 2004 and 2017. Survival was analyzed with the Kaplan–Meier method and log-rank test.

Results Median age at presentation was 14 months with male: female ratio 1.2:1. Mean duration between onset of symptoms and presentation was 49 days (standard deviation ± 79). Most common presenting symptom was white pupillary reflex in 60% of children. Family history of RB and other cancers was found in one (0.5%) and seven (4%) children, respectively. Primary mode of diagnosis and staging was ocular ultrasonography (bone scan) in 87% of patients. Computed tomographic scan and magnetic resonance imaging were done in 124 (66%) and 30 (16%) patients, respectively. International staging system grade E disease was found in 144 (76%), extraocular disease in 55 (29%), bilateral disease in 49 (26%), and trilateral disease in 3 (1.5%) children. Out of 189 children with RB, 33 (18%) refused treatment and 156 children received treatment (24 children [15%] abandoned treatment midway and 132 [85%] completed treatment). One hundred children (64%) received systemic therapy as neoadjuvant or adjuvant chemotherapy and 20 (13%) received local therapy. Eyeball and vision salvage rate with chemotherapy were 20 (13%) and 9 (6%), respectively. Cryotherapy was the most common modality of local treatment used in 11 (55%) children. Five-year survival for patients who received treatment was 76% (median survival not reached). In the treatment refusal group, median survival was 9 months.

Conclusion In developing countries, RB is mostly detected in advanced stages resulting in poor outcomes. Increased awareness and accessibility to dedicated centers for treating childhood malignancy can lead to early diagnosis, better prognosis, and increased vision salvage.

Keywords

advanced stages - chemotherapy - childhood malignancy - retinoblastoma - survival - treatment refusal

Ethics Approval and Consent to Participate

Institutional ethics committee (BBCI Medical Ethics Committee) approval was obtained for the study before reviewing the patient records and the study conformed to the Declaration of Helsinki.


Availability of Data and Material

Obtained from hospital-based case records and hospital information services.




Publication History

Article published online:
27 February 2022

© 2022. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Houston SK, Murray TG, Wolfe SQ, Fernandes CE. Current update on retinoblastoma. Int Ophthalmol Clin 2011; 51 (01) 77-91
    CrossrefPubMedGoogle Scholar
  • 2 Kivelä T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol 2009; 93 (09) 1129-1131
    CrossrefPubMedGoogle Scholar
  • 3 National Cancer Registry Programme. Consolidated Report of Hospital Based Cancer Registries; 2012–2016. Bangalore: NCDIR, Indian Council for Medical Research; 2020
    Google Scholar
  • 4 Shields JA, Shields CL. Intraocular Tumors – A Text and Atlas. Philadelphia, PA, USA: WB Saunders Company; 1992
    Google Scholar
  • 5 Abramson DH, Marr BP, Dunkel IJ. et al. Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results. Br J Ophthalmol 2012; 96 (04) 499-502
    CrossrefPubMedGoogle Scholar
  • 6 Eldebawy E, Patrocinio H, Evans M. et al. Stereotactic radiotherapy as an alternative to plaque brachytherapy in retinoblastoma. Pediatr Blood Cancer 2010; 55 (06) 1210-1212
    CrossrefPubMedGoogle Scholar
  • 7 Abouzeid H, Moeckli R, Gaillard MC. et al. (106)Ruthenium brachytherapy for retinoblastoma. Int J Radiat Oncol Biol Phys 2008; 71 (03) 821-828
    CrossrefPubMedGoogle Scholar
  • 8 Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am 2005; 18 (01) 41-53 , viii
    CrossrefPubMedGoogle Scholar
  • 9 Shields CL, Mashayekhi A, Au AK. et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology 2006; 113 (12) 2276-2280
    CrossrefPubMedGoogle Scholar
  • 10 Ortiz MV, Dunkel IJ. Retinoblastoma. J Child Neurol 2016; 31 (02) 227-236
    CrossrefPubMedGoogle Scholar
  • 11 Naik AS, Jyothi S, Shah PK. Retinoblastoma: a comprehensive review. Kerala J Ophthalmol 2016; 28: 164-170
    CrossrefGoogle Scholar
  • 12 Sahu S, Banavali SD, Pai SK. et al. Retinoblastoma: problems and perspectives from India. Pediatr Hematol Oncol 1998; 15 (06) 501-508
    CrossrefPubMedGoogle Scholar
  • 13 Singh U, Katoch D, Kaur S, Dogra MR, Bansal D, Kapoor R. Retinoblastoma: a sixteen-year review of the presentation, treatment, and outcome from a tertiary care institute in Northern India. Ocul Oncol Pathol 2017; 4 (01) 23-32 DOI: 10.1159/000477408.
    CrossrefPubMedGoogle Scholar
  • 14 Padma M, Kumar N, Nesargi PS, Aruna Kumari BS, Appaji L, Viswanathan A. Epidemiology and clinical features of retinoblastoma: a tertiary care center's experience in India. South Asian J Cancer 2020; 9 (01) 56-58
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Chawla B, Hasan F, Azad R. et al. Clinical presentation and survival of retinoblastoma in Indian children. Br J Ophthalmol 2016; 100 (02) 172-178
    CrossrefPubMedGoogle Scholar
  • 16 Truong B, Green AL, Friedrich P, Ribeiro KB, Rodriguez-Galindo C. Ethnic, racial, and socioeconomic disparities in retinoblastoma. JAMA Pediatr 2015; 169 (12) 1096-1104
    CrossrefPubMedGoogle Scholar
  • 17 Jamalia R, Sunder R, Alagaratnam J, Goh PP. Retinoblastoma registry report–Hospital Kuala Lumpur experience. Med J Malaysia 2010; 65 (Suppl A): 128-130
    PubMedGoogle Scholar
  • 18 Rojanaporn D, Attaseth T, Dieosuthichat W. et al. Clinical presentations and outcomes of retinoblastoma patients in relation to the advent of new multimodal treatments: a 12-year report from single tertiary referral institute in Thailand. J Ophthalmol 2020; 2020: 4231841 DOI: 10.1155/ 2020/4231841.
    CrossrefPubMedGoogle Scholar
  • 19 Francis JH, Roosipu N, Levin AM. et al. Current treatment of bilateral retinoblastoma: the impact of intraarterial and intravitreous chemotherapy. Neoplasia 2018; 20 (08) 757-763
    CrossrefPubMedGoogle Scholar
  • 20 Jubran RF, Erdreich-Epstein A, Butturini A, Murphree AL, Villablanca JG. Approaches to treatment for extraocular retinoblastoma: Children's Hospital Los Angeles experience. J Pediatr Hematol Oncol 2004; 26 (01) 31-34
    CrossrefPubMedGoogle Scholar
  • 21 Asencio-López L, Torres-Ojeda AA, Isaac-Otero G, Leal-Leal CA, Leal-Leal CA. Treating retinoblastoma in the first year of life in a national tertiary paediatric hospital in Mexico. Acta Paediatr 2015; 104 (09) e384-e387
    CrossrefPubMedGoogle Scholar
  • 22 Patel TN, Mallipatna AC, Merchant A. et al. Consumer Digital Cameras: A Feasible Strategy for the Early Detection of Childhood Blindness. Invest. Ophthalmol. Vis. Sci 2012; 53 (14) 6775
    Google Scholar